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ABSTRACT   
Malaria is one of the deadliest infectious diseases in the world. Immune responses to 
Plasmodium falciparum malaria vary among individuals and between populations. Human 
genetic variation in immune system genes is likely to play a role in this heterogeneity. Natural 
killer (NK) cells produce inflammatory cytokines in response to malaria infection, kill 
intraerythrocytic Plasmodium falciparum parasites by cytolysis, and participate in the initiation 
and development of adaptive immune responses to plasmodial infection. These functions are 
modulated by interactions between killer-cell immunoglobulin-like receptors (KIR) and human 
leukocyte antigens (HLA). Therefore, variations in KIR and HLA genes can have a direct 
impact on NK cell functions. Understanding the role of KIR and HLA in immunity to malaria 
can help to better characterize antimalarial immune responses. In this review, we summarize 
the different KIR and HLA so far associated with immunity to malaria.  
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Introduction  
          Malaria is one of the most serious infectious disease problems in the world (1). Malaria 
burden is greatly affected by human immunity (2, 3), especially in populations with moderate 
to high transmission intensity (4). Partial immunity to malaria is developed over years of 
exposure (5). Although this partial immunity does not provide complete protection, it reduces 
risks of parasitemia progressing to clinical illness and to severe disease (6). This explains why 
most malaria deaths in high transmission areas, such as much of sub-Saharan Africa, occur 
in children (7). Several studies have consistently shown a number of human genetic variants 
that are associated with protection from uncomplicated and severe P. falciparum malaria. 
Haemoglobin S heterozygous (HbAS) individuals are protected from uncomplicated and 
severe malaria (8, 9). Haemoglobin C (HbAC) heterozygotes (10, 11), and α–thalassemia 
heterozygotes (_α/αα) and homozygotes (_α/_α) are protected from severe malaria (8). 
However, these well-characterized polymorphisms only partially explain genetic variation in 
responses to malaria (12). It is important to identify additional human genetic variants that are 
associated with susceptibility or protection.  
         Genetic variants of human killer-cell immunoglobulin-like receptors (KIR) and human 
leukocyte antigens (HLA) are strongly associated with risks of infectious diseases (13), 
autoimmune disorders (13-15), success in cell transplantation for the treatment of 
haematopoietic malignancies (16), certain cancers (17), and pregnancy outcomes (18). KIR 
and HLA genes segregate independently on chromosomes 19 and 6, respectively, and are 
both highly diverse, with extensive allelic polymorphism (19). KIR and HLA genes are reported 
to be more polymorphic in African populations than in other populations (19).  Evolutionary 
pressure from malaria pathogens may have in part driven the high KIR and HLA genetic 
diversity in Africa (20, 21). Data regarding associations between KIR and HLA variants and 
malaria risk have been inconsistent, but since interactions between the genetically diverse 
KIR and HLA molecules modulate the functionality of natural killer (NK) cell response to 
malaria infections, these genes remain good candidates to understand the role of immune 
cells in malaria.   
           Despite recent reports indicating improvement in the control of malaria in some 
populations, and the potential for elimination of malaria from many regions of the world, P. 
falciparum malaria still causes extensive morbidity and mortality, particularly in sub-Saharan 
Africa (22). In response to the persistent malaria burden, there have been increased efforts in 
both vector control, using insecticides and malaria treatment, and chemoprevention using 
antimalarial drugs (23). However, these approaches have faced challenges of both insecticide 
and drug resistance (24). Drug discovery for new antimalarials is challenging and costly (24), 
and parasite resistance develops readily (25). Given the limitations of insecticides and 
antimalarial drugs, a highly effective malaria vaccine would significantly contribute to malaria 
control (26). Among major challenges to the development of vaccines against malaria are 
failure to induce strong innate immune responses and lack of potentiation and maintenance 
of adaptive immune responses (27).  
          There have been efforts to develop malaria vaccines since the 1940s (28). Despite 
several promising candidates, an effective vaccine that provides long-lived protection from 
malaria has not been developed (29). One vaccine candidate, RTS,S/AS01, has recently been 
approved for pilot implementation trials in sub-Saharan Africa (30). However, RTS,S/AS01 
offers only modest and short lived protection (31, 32), and the efficacy of this vaccine varies 
with malaria transmission intensity (27). Other approaches are under study, but none has yet 
yielded a highly efficacious vaccine (32). A better understanding of the role of human genetic 
variation in heterogeneous immune responses to malaria infection may facilitate vaccine 
approaches. In this review, we provide a concise overview of evidence for associations 
between KIR and HLA genetic variants and susceptibility to or protection against malaria.  
 
Killer-cell Immunoglobulin-like Receptors  
          Killer-cell immunoglobulin-like receptors (KIRs) are a family of highly polymorphic type 
1 transmembrane glycoproteins expressed on the surface of NK cells and some T cells (33), 
that bind HLA class I molecules (34)  and regulate NK cell functions (35). KIRs are encoded 
by a set of highly polymorphic genes located within the leucocyte receptor complex on human 
chromosome 19q13.4 (36). KIRs are the second most genetically diverse family in the 
mammalian genome after HLA, and they differ between individuals mainly at three levels, copy 
number variation, allelic diversity and variation in the binding specificity of individual KIRs to 
HLA class I ligands (37).   
         Sixteen KIR genes have been described to date, including genes that encode inhibitory 
(KIR3DL1-3, KIR2DL1-3 and KIR2DL5) and activating (KIR3DS1 and KIR2DS1-5) receptors 
(38). KIR2DL4 is unique because it can trigger both activation and inhibition (39). KIR2DP1 
and KIR3DP1 are pseudogenes that do not encode cell surface receptors (40). The 
nomenclature of KIR genes is based on structural and functional characteristics (41). 
Depending on whether KIR have two or three extracellular immunoglobulin domains (D), they 
are named KIR2D or KIR3D (42). Functionally, KIR with short (S) intracytoplasmic tails 
activate NK cells by pairing with the immunoreceptor tyrosine-based activation motif (ITAM) 
containing adaptor protein DAP12 and those with long (L) intracytoplasmic tails inhibit NK cell 
functions, because they contain the immunoreceptor tyrosine-based inhibitory motif (ITIM) that 
recruits phosphatase SHP-1 (43). Inhibitory KIRs however can also prime NK cells for 
functional competence if they bind to self HLA class I molecules, a process known as NK cell 
education (44).  KIR genes with two or three extracellular immunoglobulin domains and a short 
intracytoplasmic tails are named KIR2DS or KIR3DS, with specific genes identified by a suffix, 
such as KIR2DS2, KIR2SD4 or KIR3DS1 (45). KIR genes with two or three extracellular 
immunoglobulin domains and long intracytoplasmic tail are named KIR2DL or KIR3DL, with 
specific genes identified by a suffix, for example KIR2DL1, KIR2DL2, KIR3DL1 and KIR3DL2 
(45). The human KIR genes are grouped into KIR A and KIR B haplotypes (Fig. 1). Haplotype 
A comprises a fixed number of 7 KIR genes, including 3 ‘framework’ genes present in all 
haplotypes (KIR3DL3, KIR2DL4 and KIR3DL2) and KIR2DL1, KIR2DL3, KIR3DL1 and 
KIR2DS4. KIR2DS4 is the only activating KIR in this haplotype, and because it often carries a 
22bp deletion, haplotype A is thought to be mostly inhibitory. About half of the individuals in 
any population studied to date will have haplotype A (46). Most diversity in haplotype A is 
conferred by allelic polymorphism (46). By definition, all other combinations of 4-16 KIR genes 
are classified as haplotype B, including many activating KIR such as KIR2DS1, KIR2DS2, 
KIR2DS5 and KIR3DS1, in addition to KIR2DL5 (46). Diversity of haplotype B is conferred by 
gene content (46). However, within the centromeric (Cen) and telomeric (Tel) ends of the KIR 
locus, there are recombination hot spots, so that crossover can occur and generate hybrid 
haplotypes such as CenA-TelB or CenB-TelA, which by definition belong to haplotype B (47). 
KIR genes exhibit strong linkage disequilibrium (LD), and are inherited together (36). Because 
of the tight linkage disequilibrium, many disease association studies with KIR genes actually 
analyse the association with haplotypes because it is difficult to isolate the role of single KIR 
genes (48).  
          A well supported hypothesis is that KIR A is specialized in fighting infectious pathogens 
(49), while KIR B is important in influencing successful reproduction (50). How inhibitory 
receptors in haplotype A may protect against infection diseases is unclear, however there are 
at least two possibilities. The first relates to the degree of inhibition, in that weaker inhibition 
may be beneficial for successful immune responses (51). The second relates to NK cell 
education, a process that primes NK cell function through the binding of inhibitory receptors 
to self MHC molecules (52). The strength of KIR and HLA binding varies depending on the 
specific receptor-ligand pair, as well as the affinity of the pairs (53) and, in turn, it impacts on 
regulation of NK cell activity (54). Heterogeneity in KIR gene content combined with allelic 
polymorphisms may lead to extensive haplotypic diversity and highly diverse NK cell 
populations within an individual (55). KIR diversity may in turn contribute to heterogeneous 
NK cell responses to P. falciparum malaria  infection (36). 
 
Human Leucocyte Antigens 
         The HLA complex encodes the most polymorphic human genes, and it is usually thought 
that their diversity is driven by resistance to pathogens (56). The HLA complex is composed 
of genes on chromosome 6 that code for molecules that mediate antigen recognition and 
presentation, as well as immunity against infectious pathogens including P. falciparum (57). 
There are two classes of polymorphic HLA molecules based on their structure and function, 
HLA class I (HLA-A, -B and -C) and HLA class II (HLA-DR, -DQ, and -DP). HLA class I 
molecules are expressed on the surface of most nucleated cells. HLA class I and II molecules 
generally present antigenic peptides from infectious pathogens to CD8+ and CD4+ T cells, 
respectively (58). But HLA class I molecules are also major ligands for KIRs (59), and as such 
they play a role in regulation of NK cell activity (59).  KIR binding to HLA class I molecules 
involves 4 epitopes named A3/A11, Bw4, C1 and C2 found on some HLA-A, some HLA-B and 
all HLA-C allotypes. Non-classical HLA class I molecules HLA-G (60), is expressed only on 
placental cells and may play roles in reproduction (61), binding to KIR2DL4 and leukocyte Ig-
like receptor B (LILRB) while the other non-classical class I HLA-E (60) presents peptides 
derived from other HLA class I molecules to the inhibitory CD94/NKG2A receptor on NK cells 
(62) and some T cells. HLA class II molecules are confined to immunocompetent cells such 
as B lymphocytes, dendritic cells, macrophages, endothelial cells, and activated T-
lymphocytes, but their expression may be induced on other cell types (63).  
 
Immunity to malaria 
          Acquired immunity to P. falciparum malaria infection is complex, requiring a balance of 
control of both parasite growth and inflammation, as overproduction of inflammatory cytokines 
results in adverse pathological consequences (64).  Innate and adaptive immunity are both 
essential for limiting P. falciparum parasite growth and the severity of malaria infection (3, 65). 
Repeated exposure to P. falciparum results in attenuation of inflammation (66), and generation 
of antimalarial antibodies that are essential in the control of blood stage malaria infection (67, 
68). Antimalarial antibodies play an essential role in immunity to malaria in areas with high P. 
falciparum malaria transmission intensity (69). Individuals living in malaria endemic regions 
acquire immunity against severe malaria quickly, but immunity against symptomatic malaria 
and control of parasitemia requires years of repeated exposure to malaria parasites, and 
remains incomplete (70-72).  
          It has been observed that humans are protected from malaria by antibodies through two 
mechanisms. First, antibodies bind to circulating free malaria parasites and prevent them from 
invading red blood cells (73, 74), and second, antibodies from malaria-immune individuals 
bind to P. falciparum proteins on the surface of infected red blood cells. This induces antibody 
dependent cellular cytotoxicity (ADCC) by NK cells (75),  phagocytosis by monocytes, and 
engagement of effector cells via Fc-mediated interactions to mediate clearance of opsonized 
red blood cells (73)  
 
NK cells and innate immunity to P. falciparum malaria 
          In humans, NK cells are usually defined as CD3–CD56+ cells (76), and can be further 
subdivided based on CD56 expression (77). Typically, CD56dim NK cells constitute the majority 
(90%) of peripheral blood NK cells (78), whereas CD56bright NK cells are more abundant in 
secondary lymphoid tissues (79). CD56dim NK cells express high levels of the low-affinity Fc 
receptor CD16, display variegated expression of inhibitory KIR for HLA class I, and express 
high levels of perforin (80). In contrast, CD56bright NK cells express no or low levels of CD16, 
exclusively express the inhibitory receptor CD94/NKG2A but no KIR and have 10-fold lower 
perforin expression than CD56dim NK cells (81). Therefore, CD56dim and CD56bright NK-cell 
subsets are considered to perform different functional roles (Fig. 2 A). Another subset of NK 
cells, referred to as adaptive or memory NK cells develop with age in people with certain 
infections. For example, in HCMV+ individuals, adaptive NK cells can be found in blood that 
are identified by the expression of the CD94/NKG2C receptor and the CD57 marker (82).  
Adaptive NK cells are differentiated from the rest of NK cells by absence of transcription factor 
promyelocytic leukemia zinc finger (PLZF) and of signalling Fc receptor γ-chain (FcRγ) that 
are lost through epigenetic modifications (83). 
         NK cells play a vital role in the innate immune response to falciparum malaria infections 
by production of IFN-γ, inhibition of parasite growth, and cytotoxic killing of intraerythrocytic 
parasites (75).  NK cells are the first cells in peripheral blood to produce IFN- γ in response to 
P. falciparum infection (84) and also participate in the initiation and development of adaptive 
immune responses (85). It has been shown that terminally differentiated CD56neg NK cells 
expand in children after chronic malaria exposure and in those diagnosed with endemic Burkitt 
lymphoma (86). These NK cell activities can be triggered by three different but complementary 
pathways: cytokine activation (75), antibody-dependent cell-mediated cytotoxicity (ADCC) 
(75), and loss of inhibitory signalling due to downregulation of HLA class I ligands, also known 
as missing-self recognition (75). It was recently shown that CD56dim NK cells inhibit P. 
falciparum growth and kill P. falciparum within red blood cells flagged with IgG antibodies from 
individuals who live in malaria endemic areas through ADCC (Fig. 2 A). This is important 
during blood stage P. falciparum malaria infection (75).  Liver NK cells also express KIR which, 
through interactions with HLA class I molecules expressed on the surface of hepatocytes (Fig. 
2B), may modulate NK cell response to liver stage malaria infection (87). 
         In a recent study in Mali, multi-parameter flow cytometry showed an increase in the 
proportion of adaptive NK cells which were associated with lower parasitemia and protection 
from malaria infection (88). Indeed these cells enhanced ADCC response to P. falciparum–
infected red blood cells (iRBCs) in the presence of naturally acquired antibodies from malaria-
resistant individuals (88). Malaria susceptible individuals with a higher proportion of PLZF and 
FcRγ negative NK cells during the transmission season had improved odds of getting 
protected from malaria infection during the subsequent season (88). Although the most 
prominent cytokines produced by NK cells are IFN-γ and tumour necrosis factor-α (TNF-α), 
they also secrete other cytokines, including IL-10, the growth factor GM-CSF, and chemokines 
MIP-1α, MIP-1β, IL-8, and RANTES. It has been demonstrated that, production of the 
regulatory cytokine IL-10 by NK cells prevents overt pathology and death from cerebral malaria 
in mouse models (89). 
         Some studies have demonstrated that individuals may vary in their ability to elicit an 
innate immune response to malaria infection with clear implications for disease manifestations 
(4). This variation possibly arises as a result of several factors, including the strength of the 
cytokine and costimulatory signals provided to NK cells by accessory cells and differential NK 
cell maturation, depending on age and infection history. For example human cytomegalovirus 
(HCMV) modulates NK cell activity through engaging inhibitory receptors without triggering 
the activating surface receptors (90). HCMV also leads to suppression of NK cell receptor 
recognition by their HLA class ligands (91). Heterogeneity of NK cell responses to plasmodial 
infection may be attributed to interactions between NK cell receptors and their ligands, HLA 
class I molecules (84). 
           
NK cells and placental malaria 
          Placental malaria results from sequestration of P. falciparum infected erythrocytes 
within the intervillous spaces of the placenta and may cause serious pregnancy complications 
such as abortion, stillbirth, and intrauterine growth restriction (92).  Cytolysis of P. falciparum 
infected red blood cells by peripheral NK cells may be important in defence against placental 
malaria (93, 94). Previous studies have indeed shown that an increase in IFN-g expressing 
NK cells in the intervillous blood of the placenta at term is associated with a reduced risk of 
placental malaria (95) 
         A distinct population of NK cells is the most abundant leukocyte population in the decidua, 
where early in pregnancy these cells contribute to placentation and pregnancy outcomes by 
regulating trophoblast invasion and uterine vascular remodelling (96). Decidual NK cells may also 
provide first-line innate immune defence against infectious diseases including placental malaria 
(97). Decidual NK cells mainly express inhibitory KIR2DL1, KIR2DL2, and KIR2DL3, activating 
KIR2DS1, as well as KIR2DL4, which may perform inhibitory or activating functions (97). KIR 
diversity may be driven by balanced selection between pregnancy success and defence against 
pathogens (98). Certain specific combinations of KIR and HLA genes affect the susceptibility to 
certain pregnancy complications (96). Other combinations may be associated with susceptibility 
to or protection from placental malaria (99). In a study of 688 placental malaria and HIV-
coinfection in Kenya, KIR BB homozygosity was associated with protection from placental malaria 
in HIV negative pregnant women, but with susceptibility in HIV positive pregnant women (97).  
This reverse association between KIR genes and placental malaria remained only in women with 
high CD4 cell counts but not in those with low CD4 cell counts.   
KIR and immunity to P. falciparum malaria  
          The activity of NK cells in immunity against P. falciparum infection depends on a fine 
balance between the strengths of the activating and inhibitory signals induced by KIR 
molecules (100). It has been clearly shown that KIR molecules regulate NK cell mediated 
production of IFN-γ in response to P. falciparum infection, and consequently influence the 
pathogenesis and severity of malaria (101). For example, NK cells from individuals with KIR 
AB haplotypes produce greater IFN-γ responses in vitro in response to P. falciparum infection 
compared to responses in either KIR AA or KIR BB homozygous individuals (102).  
         A study of 477 malaria cases in Thailand showed association of the KIR2DL3 gene that 
marks haplotype A and of its ligand HLA-C1 with cerebral malaria. Moreover, this receptor-
ligand pair was found at lower frequency in malaria high-endemic populations, suggesting 
evidence of selection due to unhelpful NK cell responses which may increase susceptibility to 
cerebral malaria (103). However, comparing KIR genotypes of 321 children with severe and 
uncomplicated malaria with those of 314 control children, the Cen-AB haplotype was found to 
be more frequent in malaria cases in the Gambia, with more activating KIR genes (KIR2DS2 
and KIR2DS5) in very ill children, suggesting that exaggerated NK cell activation may 
contribute to the pathogenesis of severe malaria (100). Furthermore, parasitemia was higher 
in KIR AA homozygote individuals, and more frequent in controls, suggesting that more 
inhibitory A haplotype may not favour parasite clearance but may protect from severe malaria 
(100). 
         In Southwest Nigeria, KIR2DL5, KIR2DS3 and KIR2DS5 genes were overrepresented 
in individuals with asymptomatic P. falciparum parasitemia compared to those with either 
uncomplicated or severe malaria (104). Furthermore, the frequency of KIR2DS3 and KIR2DS5 
was higher in individuals with uncomplicated malaria compared to those with severe malaria 
(104). These results suggest a protective role for inhibitory KIR2DL5 and activating KIR2DS3 
and KIR2DS5 genes from severe malaria. Heterozygosity at the KIR centromeric region, Cen-
AB2, has also been shown to be more frequent in asymptomatic controls compared to 
individuals with severe malaria (104). This implies that, KIR heterozygous AB haplotypes may 
be associated with protection from severe malaria, and it has been suggested that this may 
be due to the greater proportion of educated NK cells in KIR AB heterozygous individuals. In 
Africans the centromeric region of the KIR locus, which encodes HLA-C receptors, is highly 
diverse, whereas the telomeric region encoding Bw4-specific receptors (KIR3DL1) lacks 
diversity (105). These features of KIR are consistent with ongoing selection imposed by 
malaria pathogens in Africa (105).  
         In northern India, individuals possessing KIR2DS2, KIR2DL1 and KIR2DL3 genes were 
susceptible to severe malaria (106). In this same study, a combination of KIR2DS2-HLAC1, 
KIR2DL1-HLAC2 and KIR2DL3-HLAC1 was found to be associated with increased risk of 
getting severe malaria (106). In a study of 77 Melanesian individuals with history or symptoms 
of malaria in the malaria high-endemic Solomon Islands, KIR AB heterozygosity showed 
higher frequency among 37 Plasmodium-positive individuals compared to 40 negative 
individuals (107). The non-deleted allele of KIR2DS4 (*001) was also more frequent in malaria 
positive individuals (107). Other studies have focused on functional responses of lymphocytes 
from healthy donors to P. falciparum-infected red blood cells (iRBC) and found heterogeneity 
in donor’s NK-cell IFN-γ production, which was significantly associated with KIR genotypes 
(108), showing that KIR AB heterozygosity was associated with high responses of CD56dim 
cells (109). It is difficult to draw a conclusive picture from the available evidence. While KIR 
AB heterozygosity may favour a larger number of ‘educated CD56dim NK cells that can respond 
more effectively to the infection, individuals with numerous activating KIR may mount too 
vigorous responses that may be deleterious in infected individuals. Individual KIR genes as 
well as KIR and their HLA class I ligands shown to be associated with susceptibility to or 
protection from severe malaria are summarised in Table 1.  
 
Table 1: KIR genetic variants and their HLA ligand combinations linked to 
susceptibility and protection from P. falciparum malaria 
Reference Study  Findings 
(108) NK cell responses of healthy donors to 
P. falciparum iRBCs (n =27) 
Individuals with Tel-AA KIR had a high NK cell 
response to P. falciparum in donors of European, 
Asian, and African descent 
(107) Plasmodium positive and negative 
malaria patients (n =77) 
KIR-AB heterozygotes were more frequent in 
Plasmodium-positive Melanesians 
(109) NK cell responses of healthy donors to 
infected RBCs (n =81) 
KIR-AB heterozygosity favoured IFN-g production by 
CD56dim cells in response to P. falciparum infected 
RBCs 
(103) Severe malaria (n=133), uncomplicated 
malaria (n=188) and control (n=314) 
children 
In the Gambia, parasitemia was higher in children 
with KIR-AA, however Cen-AA was more frequent in 
controls. Cen-AB more frequent in malaria cases with 
KIR-BB and HLA-C1 more frequent in very ill children 
(102) Cerebral and non-complicated malaria 
cases (n = 477) 
In Thailand, significant association of KIR2DL3 and its 
ligand HLA-C1 with cerebral malaria. Also, KIR2DL3 
and HLA-C1 less frequent in malaria high-endemic 
populations 
(96) Placental malaria in 479 HIV positive 
and 209 HIV negative pregnant women 
In Kenya, KIR-BB homozygosity was associated with 
protection from placental malaria in HIV negative 
pregnancies but susceptibility in HIV positive 
pregnancies  
(104) Severe malaria (n=201), uncomplicated 
malaria (n=153) and asymptomatic 
malaria (n=200)  
In South West Nigeria, Cen-AB less frequent in 
severe malaria, with KIR-BB more frequent in severe 
and uncomplicated malaria compared to 
asymptomatic  
(106) Cerebral malaria (n=213) 
Uncomplicated (n=87) 
North India, cerebral malaria associated with 
KIR2DS2 (B) KIR2DL1 (A) and KIR2DL3 (A). KIR-BB 





HLA genetic variants and immunity to P. falciparum malaria  
         The unique variability of the genes that encode HLA molecules and their haplotypic 
composition, especially in native Africans, is proposed to have resulted from needs to fight 
multiple and frequent deadly infectious pathogens (110). HLA class I molecules are major 
ligands for KIRs, and as such, they play a role in regulation of NK cell activity during malaria 
infection. HLA class I molecules also present malaria antigens to T cells and are therefore 
important in adaptive immunity to malaria, which is critical during liver stage P. falciparum 
malaria infection. HLA class II molecules mediate the clearance of red blood cells infected with 
P. falciparum parasites through stimulation of T helper cells (111). Some studies have clearly 
shown that HLA molecules influence antibody titres to malaria antigens, including glutamate 
rich protein and merozoite surface antigens (112). 
          Several studies have shown some HLA genetic variants to be associated with 
susceptibility or protection from severe malaria. However, results have been inconsistent 
(Table 2 A and 2B). The first study on the role of HLA in malaria described protection from 
cerebral malaria and severe malaria anaemia conferred by the HLA class I allele, HLA-Bw53, 
and the HLA class II haplotype, HLA-DRBl*1302-DQAl*0102-DQBl*0501. Molecular analysis 
revealed that liver stage antigen-I (LSA-1), a liver-stage specific antigen of P. falciparum, was 
recognized by HLA-Bw53-positive individuals. However, these findings have not been 
confirmed in other malaria endemic populations, and significant associations of malaria 
antigens other than LSA-1 with HLA molecules have not been discovered.  
          In studies of interactions between variable HLA molecules and polymorphic parasite 
factors, it has been demonstrated that the P. falciparum circumsporozoite protein binds to 
HLA-DR and HLA-DQ molecules in vitro as well as in animal models. Two HLA class II alleles, 
DRB1*04 and DPB1*1701, have been observed to be more frequent in severe, compared to 
uncomplicated malaria. HLA-B49, -A1, -B27 and HLA-DRB1*0809 was shown to be strongly 
associated with severe malaria in a study conducted in Mumbai in India (113). HLA-A19 and 
HLA-DQB1 *0203 were associated with protection from severe malaria in the same population 
(113). In a study conducted in Thailand in patients with severe cerebral malaria, HLA-B46 was 
significantly associated with risk of cerebral malaria, while HLA-B56 and HLADR1*1001 were 
associated with protection from cerebral malaria (114). In Senegal, HLA-DR3 and HLA-DR10 
were strongly associated with cerebral malaria (115). In the Gambia, HLA-B53 and HLA-
DRB1*1302 alleles were found to be strongly associated with protection from severe malaria 
(116).  
  
Table 2A: HLA class I genetic variants associated with susceptibility or protection 
against P. falciparum malaria 
Reference Country HLA class I associated with 
susceptibility to severe malaria 
HLA class I associated with 
protection from severe malaria   
(117) The Gambia - B*53 
(118) Malaysia - B*1513 
(113) Mumbai, India HLA-A1, HLA-B27 and HLA-B49  HLA-A19 
(114) Thailand HLA-B46 HLA-B56  
(119) Sardinia, Italy - B*35 
(120) New Delhi, 
India 
- A*0211 
(100) The Gambia - HLA-Cw*16:01 frequency (a C 
group 1 allele) 
 
Table 2B: HLA class II genetic variants associated with susceptibility or resistance to 
P. falciparum malaria 
Reference Country HLAs associated with susceptibility to 
malaria 
HLAs associated with protection 
against malaria   
(115) Senegal DR*3, DR*10 (cerebral malaria) - 
(121) The Gambia - DRB1*1302-DQB1 *0501 
(122) Vietnam - HLA-DQ1*0502 
(113) Mumbai, india HLA-DRB1*0809  HLA-DQB1*0203 




It is clear that interactions between KIR and HLA molecules modulate the activity of 
NK cells. The role of NK cells in responses to malaria has become established, and therefore 
it is important to decipher how KIR and HLA immunogenetics regulate susceptibility to or 
protection from malaria, in order to understand the heterogeneous responses of populations 
to malaria infection. This in turn may help understand malaria transmission and severity in 
specific populations and inform specific malaria control intervention.  
Several studies have suggested that certain KIR and HLA variants are associated with 
malaria but there are challenges at different levels to draw a comprehensive picture of how 
KIR and HLA variants contribute to susceptibility to or protection against malaria. Some 
challenges are related to population genetics, some to parasite genetics and others to the 
biology of KIR and HLA immunogenetics. First of all, some of these studies are conducted 
with small sample sizes, emphasizing the need to study larger populations in Africa and other 
malaria endemic populations, particularly to accommodate for allelic diversity. Different 
populations may have selected different KIR and HLA variants. Other infectious pathogens 
prevalent in certain malaria endemic populations may also exert selective pressure on immune 
responses, thus shaping the diversity of KIR and HLA in those populations. Therefore, the role 
of other co-infections should be considered in studies involving KIR and malaria especially in 
populations with many infectious pathogens. Different species of parasites may infect different 
populations and unique antigenic drifts may occur in parasites in different populations. How 
the binding between certain KIR and HLA molecules regulate NK cell function in the context 
of any given disease is still very challenging to determine. In the case of malaria, knowledge 
of the rich KIR allelic diversity in African populations and their binding affinities to equally 
diverse HLA ligands is still being sought. KIR can either inhibit or enhance NK cell effector 
functions. Combinations of KIR and HLA determine both NK cell education – that is the priming 
of effector function – and effector function themselves. However, because inhibitory KIR and 
other inhibitory receptors (e.g. CD94/NKG2A) contribute to education and effector function in 
opposite ways (i.e. they promote education but suppress function), it may be difficult to 
recreate how KIR and HLA immunogenetics determine the biology of NK cells during malaria 
infection. For example, inhibitory interactions may be necessary to educate NK cell to mediate 
ADCC required to eliminate iRBC, but not required or even counterproductive to activate IFN-
g production by NK cells upon interaction with HLA class I-expressing infected cells.  
Finally, evolutionary pressure from P. falciparum malaria pathogens might have 
selected for certain KIR and HLA genetic variants that protect against severe malaria but 
increase the risk of other diseases, as it has been well documented for sickle cell disease and 
other hemoglobinopathies. For example, the high frequency in sub-Saharan Africa of certain 
KIR and HLA variants associated with pregnancy complications (123), may be the result of 
the trade-off for the selection of genetic variants that protect against malaria.  
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Figure 1. KIR haplotypes.  
KIR haplotypes A and B are present in all populations worldwide. A recombination hotspot between 
KIR3DP1 and KIR2DL4 separates the Centromeric form the Telomeric end of both types of 
haplotype. KIR A haplotype is composed of mainly inhibitory KIR except for KIR2DS4. Allelic 
polymorphism is very high in the KIR A haplotype (KIR3DL1, 3DL2 and 3DL3 have > 100 alleles, 
2DL1 and 2DL3 have ~ 50 alleles). Haplotypes B have several activating receptors, with variable 
number of genes (4-20) and less allelic polymorphisms. Some KIR B haplotypes are made up of 
combinations of haplotypes A and B (CenA-TelB, CenB-TelA). HLA epitopes bound by some KIR 
are known and indicated as C1, C2 or Bw4. 
  





Figure 2. NK receptors and responses to malaria.  
NK cell responses to malaria may be either beneficial if they target the parasite or detrimental if 
they contribute to immunopathology. The binding of HLA receptors (CD94/NKG2A or KIR) to self 
HLA molecules affects both how NK cells are primed for function in steady state and how they 
function during an immune response. In steady state, the binding of HLA molecules on 
haematopoietic cells by inhibitory NK-cell receptors such as NKG2A (binds HLA-E) and KIR (bind 
HLA-A, -B and -C) prime NK cells to become functionally competent. The process of acquiring 
functional competence through the binding of inhibitory receptors to self HLA molecules on 
haematopoietic cells is referred to as “NK cell education”.  The binding of the same inhibitory 
receptors to HLA molecules on potential target cells during an immune response, however, 
suppresses NK cell function. A) For example, CD56bright NK cells that do not express KIR can be 
educated by NKG2A binding to HLA-E to produce IFN-g during immune responses to malaria. On 
the other hand, CD56dim NK cells that express inhibitory KIR (e.g. KIR2DL1 or KIR3DL1 in a KIR 
A haplotype) for self HLA (e.g. HLA-C2 or HLA-Bw4, respectively) found on haematopoietic cells 
are educated to recognise and kill infected red blood cells that do not express HLA molecules and 
therefore cannot suppress KIR2DL1+ and KIR3DL1+ CD56dim NK cells during immune responses 
to blood stage malaria. CD56dim cells can also mediate ADCC because they express CD16, which 
binds antibody through its Fc portion. B) Liver NK cells are made up of different subsets, some of 
which express both KIR and NKG2A, and both these receptors can educate liver NK cells by 
binding HLA-A, -B, -C or -E on haematopoietic cells in steady state. On the other hand, during liver 
stage malaria, both receptors can suppress NK cell functions when NK cells interact with infected 
hepatocytes that express cognate HLA molecules.  
 
